These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38771472)

  • 1. The Efficacy and Safety of Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors in Real-World Clinical Practice: Potential Cautionary Use in Elderly Patients with Type 2 Diabetes (T2D).
    Lee DH; Oh JH; Jeon HJ; Oh TK
    Diabetes Ther; 2024 Jul; 15(7):1615-1626. PubMed ID: 38771472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Toyama T; Oshima M; Jun M; Chin KL; Hawley CM; Zoungas S
    Cochrane Database Syst Rev; 2020 Jul; 8(8):CD009966. PubMed ID: 32803882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.
    Zaccardi F; Webb DR; Htike ZZ; Youssef D; Khunti K; Davies MJ
    Diabetes Obes Metab; 2016 Aug; 18(8):783-94. PubMed ID: 27059700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.
    Whalen K; Miller S; Onge ES
    Clin Ther; 2015 Jun; 37(6):1150-66. PubMed ID: 25891804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
    Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of sodium-glucose cotransporter 2 inhibitors (SGLT2i) during the month of Ramadan in patients with type 2 diabetes mellitus in Pakistani population-an observational study from a tertiary care center in Karachi.
    Sheikh A; Das B; Sattar S; Islam N
    Endocrine; 2023 Apr; 80(1):64-70. PubMed ID: 36580199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus.
    Kinduryte Schorling O; Clark D; Zwiener I; Kaspers S; Lee J; Iliev H
    Adv Ther; 2020 Aug; 37(8):3463-3484. PubMed ID: 32372290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study.
    Ku EJ; Lee DH; Jeon HJ; Oh TK
    Diabetes Res Clin Pract; 2019 May; 151():65-73. PubMed ID: 30954510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.
    Ji L; Ma J; Li H; Mansfield TA; T'joen CL; Iqbal N; Ptaszynska A; List JF
    Clin Ther; 2014 Jan; 36(1):84-100.e9. PubMed ID: 24378206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Effectiveness of Quadruple Combination Therapy with Empagliflozin Versus Basal Long-Acting Insulin Therapy in Patients with Type 2 Diabetes: 3-Year Retrospective Observational Study.
    Ku EJ; Oh TK
    Diabetes Ther; 2023 Sep; 14(9):1471-1479. PubMed ID: 37369826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementation of chronic kidney disease guidelines for sodium-glucose co-transporter-2 inhibitor use in primary care in the UK: a cross-sectional study.
    Forbes AK; Hinton W; Feher MD; Elson W; Joy M; Ordóñez-Mena JM; Fan X; Cole NI; Banerjee D; Suckling RJ; de Lusignan S; Swift PA
    EClinicalMedicine; 2024 Feb; 68():102426. PubMed ID: 38304744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Dholariya S; Dutta S; Singh R; Parchwani D; Sonagra A; Kaliya M
    Expert Opin Pharmacother; 2023; 24(18):2187-2198. PubMed ID: 37817422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
    Birkeland KI; Jørgensen ME; Carstensen B; Persson F; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Nyström T; Eriksson JW; Bodegård J; Norhammar A
    Lancet Diabetes Endocrinol; 2017 Sep; 5(9):709-717. PubMed ID: 28781064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Comparative Study of efficacy and safety of different Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitors in the Management of Patients with Type II Diabetes Mellitus.
    Bhosle D; Indurkar S; Quadri U; Chandekar B
    J Assoc Physicians India; 2022 Jun; 70(6):11-12. PubMed ID: 35702841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Korean Patients with Type 2 Diabetes Mellitus in Real-World Clinical Practice.
    Hong AR; Koo BK; Kim SW; Yi KH; Moon MK
    Diabetes Metab J; 2019 Oct; 43(5):590-606. PubMed ID: 30877709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of sodium-glucose co-transporter 2 inhibitors in solid organ transplant recipients with pre-existing type 2 or post-transplantation diabetes mellitus: A systematic review.
    Lin Y; Mok M; Harrison J; Battistella M; Farrell A; Leung M; Cheung C
    Transplant Rev (Orlando); 2023 Jan; 37(1):100729. PubMed ID: 36427372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Efficacy and Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors as Add-On Therapy in Patients With Type 2 Diabetes.
    Hussain M; Elahi A; Iqbal J; Bilal Ghafoor M; Rehman H; Akhtar S
    Cureus; 2021 Apr; 13(4):e14268. PubMed ID: 33954073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years.
    Liu XY; Zhang N; Chen R; Zhao JG; Yu P
    J Diabetes Complications; 2015; 29(8):1295-303. PubMed ID: 26365905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.